[Initial and unique treatment of macular edema due to branch retinal vein occlusion with antiangiogenic agents. A comparative pilot study].
Gallego-Pinazo
R
R
Francés
E
E
Gómez
M J
MJ
López
R
R
Díaz-Llopis
M
M
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D010865:Pilot Projects; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000069579:Ranibizumab